Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 39

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 39
---
 therefore instead recognized as Acquisition and integration related charges in Genmab’s Condensed Consolidated Statements of Comprehensive Income during the second quarter of 2024.

The acquisition has been accounted for using the acquisition method of accounting which requires that assets acquired and liabilities assumed be recognized at their fair values as of the Acquisition Date and consolidated into Genmab’s Condensed Consolidated Balance Sheets. The results of operations for ProfoundBio have been

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 32/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
included in Genmab’s consolidated financial statements from the Acquisition Date. A fair value measurement has been performed and the purchase price has been allocated to intangible assets, associated deferred tax liabilities, other assets and liabilities, as well as goodwill being the excess value of the purchase price over the fair value of assets acquired and liabilities assumed (the purchase price allocation). Adjustments may be applied to the purchase price allocation for a period of up to 12 months from the Acquisition Date and was therefore finalized during the second quarter of 2025. During the fourth quarter of 2024, the Company recorded a measurement period adjustment impacting non-current deferred tax liabilities and goodwill that was not material.

The total consideration for the acquisition of ProfoundBio is summarized as follows:

|                                                                      |     | Total Consideration |       |
| Cash paid for outstanding shares                                     |     |                     | 1,718 |
| Cash for equity compensation attributable to pre-combination service |     |                     |   187 |
| Total consideration                                                  |     |                     | 1,905 |
| Cash acquired                                                        |     |                     |  -122 |
| Cash used for acquisition of business                                |     |                     | 1,783 |

The purchase price allocation resulted in the following amounts being allocated to the assets acquired and liabilities assumed at the Acquisition Date based upon their respective fair values summarized below:

|                                      |     | Amounts Recognized as of the Acquisition Date |       |
| Cash and cash equivalents            |     |                                               |   122 |
| Other current assets*                |     |                                               |     4 |
| Property and equipment               |     |                                               |     6 |
| IPR&D